Neovasc Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending March 31, 2022 was 535.39% (a 14.79% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue decreased by -6.5%
  • Annual Research and Development Expense of Revenue for 2021 was 592.17% (a -41.8% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2020 was 1017.42% (a 8.81% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 935.06% (a 4.32% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending March 31, 2022 was 511.58% (a -13.74% decrease compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue decreased by -41.16% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
511.58% 593.07% 750.57% 869.44%
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of Neovasc Inc.

Most recent Research and Development Expense of Revenueof NVCN including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of Neovasc Inc.

Neovasc Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 535.39%
2021 466.42% 484.74% 572.58% 998.06% 592.17%
2020 1100.84% 878.46% 1616.09% 848.83% 1017.42%
2019 1211.66% 954.49% 942.99% 723.8% 935.06%
2018 889.01% 726.47% 952.2% 1176.64% 896.32%
2017 306.46% 321.67% 325.71% 341.13% 317.44%
2016 175.08% 156.32% 333.45% 203.46% 203.56%
2015 204.59% 198.14% 146.22% 148.88% 173.03%
2014 169.23% 84.88% 70.77% 31.88% 80.8%
2013 71.5% 51.46% 57.51% 49.12% 58.28%
2012 42.56% 47.15% 71.03% 48.54% 50.9%
2011 0.0% 49.9%

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.